ESTRO 2023 - Abstract Book

S1001

Digital Posters

ESTRO 2023

one in the morning and two in the afternoon. The repeatability of the recognized windows was evaluated in relation to durations and time placements. For each single patient and within her activity windows, inference has been made on HR and STP variation highlighting a negative trend for the median STP and an increase of HR median values. Using FT, we were not able to identify a trend for SLP. Conclusion Using smart wearable devices already available on the market it is possible to non-invasively collect qualitative biomedical data related to patient activity windows. By monitoring HR and STP median trends during such windows, medical staff can perform an evaluation of RIF based on objective data. As regard to SLP, more suitable devices are needed to get to a reliable study on sleep quality variation during RT time. Future developments of our research is focusing on ballistocardiograph data collected with the help of non-invasive pressure sensors under patient beddings. S. Arculeo 1 , S. Dicuonzo 2 , A. Morra 3 , M.A. Gerardi 4 , L. Colombi 5 , C. Lorenzo 6 , F. Cattani 7 , S. Comi 8 , P. Veronesi 9 , V. Galimberti 10 , M. Zaffaroni 3 , M.A. Zerella 3 , R. Orecchia 11 , M.C. Leonardi 7 , B.A. Jereczek-Fossa 3,12 1 IEO European Institute of Oncology IRCCS, Division of Radiation Oncology , Milan , Italy; 2 IEO European Institute of Oncology IRCCS , Division of Radiation Oncology , Milan, Italy; 3 IEO European Institute of Oncology IRCCS, Division of Radiation Oncology, Milan , Italy; 4 IEO European Institute of Oncology IRCCS, Milan, Division of Radiation Oncology, Milan , Italy; 5 IEO European Institute of Oncology IRCCS, Division of Radiation Oncology, Milan, Italy; 6 University of Milan, Department of Oncology and Hemato-Oncology , Milan, Italy; 7 IEO European Institute of Oncology IRCCS, Division of Radiation Oncology, Milan, Italy; 8 IEO European Institute of Oncology IRCCS, Division of Radiation Oncology, Milano, Italy; 9 IEO European Institute of Oncology IRCCS, Division of Senology, Milan, Italy; 10 IEO European Institute of Oncology IRCCS, ivision of Senology, Milan , Italy; 11 IEO European Institute of Oncology IRCCS, Scientific Direction, Milan, Italy; 12 University of Milan, , Department of Oncology and Hemato-Oncology, Milan, Italy Purpose or Objective Although the standard treatment of in-breast recurrence (IBR) after breast conservative surgery (BCS) and whole breast radiotherapy (WBRT) is still represented by mastectomy, over the last decade there has been an increasing attitude towards performing a second BCS followed by further radiotherapy (RT) with different techniques (intraoperative RT, brachytherapy, external beam RT). The aim of the study is to evaluate chronic toxicity and local control of partial breast re-irradiation (re-PBI) with intensity modulated RT (IMRT), using a hypofractionated scheme Materials and Methods Eligibility criteria included patients previously treated with WBRT who experienced IBR and were operated on with second BCS. Re-irradiation was limited to the tumor bed and was performed using either TomoTherapy® IMRT with helical modality or BrainLab-VERO® IMRT step-and-shoot. Planning target volume (PTV) was generated by clinical target volume (CTV) with a margin of 5 mm. Daily image guided RT was applied by megavoltage fan beam computerized tomography (CT) for TomoTherapy® and kilovoltage cone beam CT for VERO®. For target volume, the PTV planning objectives were V100% ≥ 95%, V95% ≥ 98%, V90% ≥ 100%, Dmax ≤ 110%. Toxicity was evaluated using LENT-SOMA scale Results Between 6/2012 and 3/2018, 59 patients were treated with re-PBI. Prescription dose was 37.05 Gy in 13 fractions. Fifteen (25%) patients were treated with TomoTherapy® and 44 (75%) with VERO®. Overall, median follow-up was 68 months. Data of chronic toxicity > 1 year are available for 44 (74%) patients; 5%,10%, 5% of patients report fibrosis G3, atrophy G2 and teleangectsia G2, respectively. Thirtenn (22%) patients showed a subsequent oncologic event after the retreatment: 1 patient had a second IBR distant from the re-PBI field (1.6% cumulative incidence of IBR), 1 patient had regional recurrence, 7 patients developed distant metastasis (lymph nodes, lung, bones and brain) and 3 had other primitive tumors. Conclusion Re-PBI after second BCS represents a feasible alternative to mastectomy with regard to local control, showing good toxicity profile. Longer follow-up is needed to evaluate late toxicity and to establish the role of this treatment modality in local control. Longer follow-up is needed to evaluate late toxicity and to establish the role of this treatment modality in local control. B. Gil Haro 1 , C. De La Fuente Alonso 1 , J. Romero Fernández 1 , S. Córdoba Largo 1 , J. Velasco Jiménez 1 , R. Benlloch Rodríguez 1 , M. Hernández Miguel 1 , M. López Valcárcel 1 , I. Zapata Paz 1 , S. Santana Jiménez 1 , P. Sarrión Rubio de la Torre 1 , M.I. García Berrocal 1 , M.R. Magallón Sebastián 1 , U.A. Corro Verde 2 , E. Ramírez Medina 3 , M. Artés Caselles 4 1 Puerta de Hierro Majadahonda University Hospital, Radiation Oncology, Madrid, Spain; 2 Marqués de Valdecilla University Hospital, Radiation Oncology, Santander, Spain; 3 Puerta de Hierro Majadahonda University Hospital, Gynecology, Madrid, Spain; 4 Puerta de Hierro Majadahonda University Hospital, General Surgery, Madrid, Spain Purpose or Objective To evaluate clinical outcomes and long-term quality-of-life (QoL) in patients treated with mastectomy or breast conservation surgery (BCS) plus adjuvant radiotherapy (RT) for ductal carcinoma in-situ (DCIS). PO-1251 Partial breast re-irradiation with IMRT for local recurrence after whole breast radiotherapy PO-1252 Comparison between treatment options for breast-DCIS: Clinical outcomes and quality of life

Materials and Methods